Exciting news for Nurosene Health Inc. ($MEND.c $MNNDF) yesterday as they announced a partnership with Cyclica to accelerate drug discovery and novel drug development targeting neurodegenerative diseases, a market valued at almost USD$40B.
Nurosene will lead in the discovery phase of the research process by identifying specific drug targets, leveraging NetraHealthAtlas (NHA), one of Nurosene's core proprietary AI tools, to accelerate identification while significantly reducing the cost and time associated with bringing a drug to the market.
NHA creates highly accurate hypotheses about invisible causal factors from patient sub-populations and then recommends ways to target diseases by exploring the necessary biochemistry involved.
Cyclica is a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline. Using their AI-augmented drug discovery platform, Cyclica will focus on discovering novel drug candidates for drug targes discovered by NHA
I'm looking forward to the results of this partnership as it has the potential to make revolutionary drug discoveries for neurodegenerative diseases.
https://www.biospace.com/article/releases/nurosene-and-amp-cyclica-partner-to-develop-novel-drugs-for-neurodegenerative-diseases/